Mandate

Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue

April 01, 2011

Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.

Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.

Related

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson

Vinge has advised Accent Equity VI and the minority shareholders on their divestment of Malte Månson to Citira, a European tire management provider and portfolio company of Norvestor. Headquartered in Stockholm, Malte Månson is an independent service and repair provider for commercial vehicles and operates a network of 28 service workshop locations across Sweden, authorized by brands such as MAN, DAF, IVECO, Mercedes-Benz, Setra, VDL and EVO. Malte Månson has an annual revenue of SEK 800 million and employs over 300 full-time professionals.
June 08, 2026

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026